These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 35333692)
21. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera. Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046 [TBL] [Abstract][Full Text] [Related]
22. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. Halfmann PJ; Uraki R; Kuroda M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Kawaoka Y EBioMedicine; 2023 Jul; 93():104677. PubMed ID: 37352827 [TBL] [Abstract][Full Text] [Related]
23. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385 [TBL] [Abstract][Full Text] [Related]
24. Long-term immunity in convalescent Syrian hamsters provides protection against new-variant SARS-CoV-2 infection of the lower but not upper respiratory tract. Stauft CB; Selvaraj P; Lien CZ; Starost MF; Wang TT J Med Virol; 2022 Jun; 94(6):2833-2836. PubMed ID: 35128693 [TBL] [Abstract][Full Text] [Related]
25. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350 [TBL] [Abstract][Full Text] [Related]
26. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Imai M; Iwatsuki-Horimoto K; Hatta M; Loeber S; Halfmann PJ; Nakajima N; Watanabe T; Ujie M; Takahashi K; Ito M; Yamada S; Fan S; Chiba S; Kuroda M; Guan L; Takada K; Armbrust T; Balogh A; Furusawa Y; Okuda M; Ueki H; Yasuhara A; Sakai-Tagawa Y; Lopes TJS; Kiso M; Yamayoshi S; Kinoshita N; Ohmagari N; Hattori SI; Takeda M; Mitsuya H; Krammer F; Suzuki T; Kawaoka Y Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16587-16595. PubMed ID: 32571934 [TBL] [Abstract][Full Text] [Related]
27. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2. Chiba S; Halfmann PJ; Iida S; Hirata Y; Sato Y; Kuroda M; Armbrust T; Spyra S; Suzuki T; Kawaoka Y Vaccine; 2023 Sep; 41(41):6025-6035. PubMed ID: 37635002 [TBL] [Abstract][Full Text] [Related]
28. Epitope Coverage of Anti-SARS-CoV-2 Nucleocapsid IgA and IgG Antibodies Correlates with Protection against Re-Infection by New Variants in Subsequent Waves of the COVID-19 Pandemic. Mullins MO; Smith M; Maboreke H; Nel AJM; Ntusi NAB; Burgers WA; Blackburn JM Viruses; 2023 Feb; 15(2):. PubMed ID: 36851798 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model. Yadav PD; Mohandas S; Shete AM; Nyayanit DA; Gupta N; Patil DY; Sapkal GN; Potdar V; Kadam M; Kumar A; Kumar S; Suryavanshi D; Mote CS; Abraham P; Panda S; Bhargava B Vector Borne Zoonotic Dis; 2022 May; 22(5):289-296. PubMed ID: 35580212 [No Abstract] [Full Text] [Related]
30. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants. Stauft CB; Selvaraj P; D'Agnillo F; Meseda CA; Liu S; Pedro CL; Sangare K; Lien CZ; Weir JP; Starost MF; Wang TT Nat Commun; 2023 Jun; 14(1):3393. PubMed ID: 37296125 [TBL] [Abstract][Full Text] [Related]
31. Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. Facciuolo A; Van Kessel J; Kroeker A; Liao M; Lew JM; Falzarano D; Kelvin AA; Gerdts V; Napper S Front Microbiol; 2023; 14():1148255. PubMed ID: 37065160 [TBL] [Abstract][Full Text] [Related]
32. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK Front Immunol; 2021; 12():793953. PubMed ID: 34899762 [TBL] [Abstract][Full Text] [Related]
33. Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection. Li H; Zhao X; Li J; Zheng H; Zhao Y; Yang J; Zhou J; Yang F; Chen Y; Zuo Y; Lai Q; Long H; Li Y; Jin W; Shi H; Liu L Viruses; 2022 Jul; 14(8):. PubMed ID: 35893674 [TBL] [Abstract][Full Text] [Related]
35. [Clinical symptoms and signs in hamsters during experimental infection with the SARS-CoV-2 virus (Coronaviridae: Tuyskanova MS; Zhugunissov KD; Ozaslan M; Myrzakhmetova BS; Kutumbetov LB Vopr Virusol; 2023 Dec; 68(6):513-525. PubMed ID: 38156567 [TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417 [TBL] [Abstract][Full Text] [Related]
37. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Zhou D; Chan JF; Zhou B; Zhou R; Li S; Shan S; Liu L; Zhang AJ; Chen SJ; Chan CC; Xu H; Poon VK; Yuan S; Li C; Chik KK; Chan CC; Cao J; Chan CY; Kwan KY; Du Z; Lau TT; Zhang Q; Zhou J; To KK; Zhang L; Ho DD; Yuen KY; Chen Z Cell Host Microbe; 2021 Apr; 29(4):551-563.e5. PubMed ID: 33657424 [TBL] [Abstract][Full Text] [Related]
38. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415 [TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 B.1.1.7 Infection of Syrian Hamster Does Not Cause More Severe Disease, and Naturally Acquired Immunity Confers Protection. Nuñez IA; Lien CZ; Selvaraj P; Stauft CB; Liu S; Starost MF; Wang TT mSphere; 2021 Jun; 6(3):e0050721. PubMed ID: 34133199 [TBL] [Abstract][Full Text] [Related]